Drug Detail

Information about Atezolizumab

Generic Name	Atezolizumab
IND	MPDL3280A
Brand Name (US)
Manufacturer	Hoffman-La Roche
Drug Type	Immunotherapy
Delivery	Intravenous
Approval Status	Phase 3
Indications
Overall Strategy	Immune system
Strategy	Immunotherapy
Drug Category	PD-L1 inhibitor

The FDA has twice designated this drug as a breakthrough therapy.

An engineered anti PD-L1 antibody.

MPDL3280A (also known as anti-PDL1 and RG7446) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1. MPDL3280A is designed to target PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on the surface of T cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.